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Epithelial–mesenchymal transitions u m m a r y
Recent clinical results for PD-1 blockade therapy have demonstrated durable tumor control with minimal
immune-related adverse effects. PD-L1 is induced in non-lymphoid tissue cells and tumor cells, in
addition to tissue-recruiting immune cells, under inﬂammatory conditions triggered by several cytokines,
especially IFN-c, and exogenous stimuli delivered by pathogen-associated molecular patterns. Receptor-
mediated signaling molecules that affect the cell cycle, proliferation, apoptosis, and survival (including
NF-jB, MAPK, PI3K, mTOR, and JAK/STAT) are involved in PD-L1 induction. PD-L1 expression in tumor
cells is also triggered by the signals described above, but in some instances, intrinsic cell alteration asso-
ciated with carcinogenesis contributes to PD-L1 induction. The tumor suppressor genes PTEN and Lkb1
and epithelial–mesenchymal transition-related molecules are also involved in the regulation of PD-L1
expression. Notably, squamous cell carcinoma of the head and neck (SCCHN) often exhibits both host
immunosuppression and cytogenetic alternations of tumor cells. Precise understanding of how PD-L1
expression is controlled will allow the development of effective approaches to PD-1 blockade therapy
for patients with SCCHN.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Antigen-speciﬁc T cell responses are controlled by the balance
between co-stimulatory and co-inhibitory signals [1,2].
Modulation of such co-signal pathways is beneﬁcial when immune
intervention is necessary. To date, four immunomodulatory biolog-
icals that target co-signal pathways have been approved for clinical
use: Abatacept (a fusion protein composed of the Fc region of
human immunoglobulin (Ig) G1 fused to the extracellular domain
of CTLA-4), Belatacept (a fusion protein composed of the Fc region
of human IgG1 fused to the extracellular domain of CTLA-4, with
two amino acid exchanges), Ipilimumab (a humanized anti-CTLA-
4 monoclonal antibody (mAb)), and Nivolumab (a humanized
anti-PD-1 mAb) (Fig. 1) [3,4]. The ﬁrst two agents target CD28-
CD80/CD86 co-stimulatory pathways and are used to achieve
immune suppression in patients with autoimmune diseases or
those who have undergone transplantation. The latter two agents
target either the CTLA-4 [5,6] or PD-1 [7–9] co-inhibitory pathway
and are used as immunostimulatory drugs in cancer therapy.Under normal physiological conditions, co-inhibitory pathways
play important roles in the maintenance of self-tolerance and in
protection against excessive tissue damage induced by immune
responses. Thus, such pathways function as immune checkpoints
[10,11]. The contributions of two immune checkpoint receptors,
CTLA-4 and PD-1, are quite different, because the expression of
both the receptors and their ligands is controlled differentially in
both time and space during progression of an immune response
(Table 1) [1,2,5,6,8,12]. Differential contributions of the CTLA-4
and PD-1 co-inhibitory receptors create different expression phe-
notypes in mice singly deﬁcient for either receptor, and different
clinical effects are evident upon application of blockade therapy.
In contrast to CTLA-4-deﬁcient mice, which develop rapidly
progressing lethal systemic lymphoproliferative disorders accom-
panied by inﬁltration of multiple organs by activated polyclonal
T cells, PD-1-deﬁcient mice exhibit slow, strain-speciﬁc, and
organ-speciﬁc diseases of autoimmunity including lupus-like
proliferative arthritis and glomerulonephritis (on the C57BL/6
background), and dilated cardiomyopathy (on the BALB/c back-
ground). CTLA-4 blockade (treatment with ipilimumab) in patients
with advanced melanoma prolonged survival. However new types
of adverse event, namely immune-related adverse events (irAE)
such as colitis, hepatitis, dermatitis, endocrinopathies, and
222 P. Ritprajak, M. Azuma /Oral Oncology 51 (2015) 221–228neuropathies were often observed [13,14]. A recent retrospective
review from 14 completed phase I-III trials of ipilimumab in
patients with advanced melanoma indicated that irAE occurred
in 64.2% of patients [15]. Grade 3 to 4 irAE have been reported in
around 20–30% of patients, depending on clinical trials [16].
PD-1 blockade (treatment with nivolumab) in patients with
treatment-refractory solid tumors gives durable and persistent
tumor regression with minimal irAE [17–21]. A study of 107
patients with melanoma who initiated treatment with nivolumab
between 2008 and 2012 revealed that overall survival was
16.8 months; 1- and 2-year survival rates were 62% and 43%,
respectively [20]. Objective responses were observed in 31% of
patients (33 of 107) and durable responses were observed for all
doses tested (0.1–10 mg/Kg). The appearance of irAE was 54%,
but grade 3–4 adverse events were only seen in ﬁve patients
(5%). PD-1 blockade seems to beneﬁt from less toxicity than
CTLA-1 blockade. PD-L1 expression in tumor cells is associated
closely with the clinical response to anti-PD-1 therapy [18,21].
However, this also implies that some patients with PD-L1-express-
ing tumor cells will not beneﬁt from anti-PD-1 therapy. A recent
phase 1 trial of combined therapy with ipilimumab and nivolumab
in 53 patients with advanced melanoma showed an objective-
responses rate was 40% and grade 3–4 adverse events in 53% of
patients, values similar to those for monotherapy [22].
To predict the efﬁcacy of and optimize anti-PD-1 therapy, alone
or in combination, it is important to understand the mechanisms
controlling PD-L1 expression. In this review, we focus on the regu-
lation of PD-L1 expression in both non-lymphoid tissue cells and
malignant cells with a particular focus on epithelial cells and squa-
mous cell carcinoma (SCC), and we discuss intrinsic and extrinsic
regulation of PD-L1 expression.PD-L1 expression in epithelial cells
PD-1 interacts with two ligands, PD-L1 (B7-H1, CD274) and PD-
L2 (B7-DC, CD273), which exhibit quite different expression
patterns [23]. Although PD-L1 is abundant in immune cells and
parenchymal tissue cells, PD-L2 expression is very limited in
dendritic cells and macrophages after activation. PD-L1 expression
at the mRNA level is high in normal human organs including theFig. 1. Immunomodulatory biologicals targeting co-signal pathways. Antigen-speciﬁc T
Abatacept and belatacept block the CD28:CD80/CD86 co-signal pathway, while ipilimuma
pathway, respectively. Blockade of co-stimulatory or co-inhibitory pathways efﬁcientlyheart, skeletal muscle, placenta and lungs, as well as in the heart
and lungs of mice; however, PD-L1 protein expression in healthy
subjects was not detectable immunohistochemically using an
anti-PD-L1 mAb [8,24,25], because of the lower sensitivity of histo-
logical staining using antibodies. Interestingly, PD-L1 protein is
induced in various non-lymphoid tissue cells, including epithelial,
endothelial, smooth muscle cells, in response to inﬂammatory
cytokines present at disease sites [26–32]. In the oral mucosa
and skin of patients with lichen planus (a chronic inﬂammatory
mucocutaneous disease characterized by massive T cell inﬁltration
under the epithelium), substantial expression of PD-L1 was
detected in keratinocytes (KCs) located near the basement mem-
brane [29]. PD-L1 protein expression in primary cultured human
oral KCs was upregulated upon stimulation with IFN-c, TNF-a, or
IL-1b. Of these effectors, IFN-c induced PD-L1 expression most
potently. Similarly, IFN-c enhanced PD-L1 expression markedly
in murine epidermal KC in vitro [33]. In a murine contact hypersen-
sitivity (CH) model, the hapten 2, 4-dinitroﬂuorobenzen (DNFB)
induced high levels of PD-L1 on epidermal KCs [33]. In inﬂamed,
but not normal skin, PD-L1 is expressed by subsets of microvessels
and KCs [34]. PD-L1 in dermal ﬁbroblasts is also induced by IFN-c
stimulation [35]. PD-L1 expression in renal tubular epithelial cells
(TEC) may be detected in patients with renal diseases such as inter-
stitial nephritis, lupus nephritis, and IgA nephropathy [36]. B7-H1
expression on TEC was induced via stimulation with IL-1a, LPS,
TNF-a, or anti-CD40 mAb. These results indicate that epithelial
PD-L1 expression is induced by inﬂammatory stimuli both
in vitro and in vivo.Immune regulation by epithelial cell-associated PD-L1
Demonstration of an actual contribution of tissue-associated
PD-L1 to disease requires ingenuity, because PD-L1 is easily induc-
ible in both non-lymphoid tissue cells and tissue-inﬁltrating
immune cells such as T cells, dendritic cells, and macrophages
in vivo. Studies using PD-L1-deﬁcient mice, bone marrow chimera
systems, and/or PD-L1 transgenic mice revealed the contributions
of pancreatic islet cell-associated PD-L1 in autoimmune diabetes
[37], of graft tissue-associated PD-L1 in organ transplantationcell responses are controlled by the valance of co-stimulation and co-inhibition.
b and nivolumab block the CTLA-4:CD80/CD86 and PD-1:PD-L1/PD-L1 co-inhibitory
inhibits or enhances T cell-mediated immune responses.
Table 1
Comparison between CTLA-4 and PD-1 immune checkpoint receptors.
Issue CTLA-4 PD-1
Expression in T cells Early activated T cells Effector T cells
Natural regulatory T cells Induced regulatory T cells
Tumor-inﬁltrating CD8 + T cells
Surface expression on T cells Transient and low Stable and high
Expression other than T cells None B cells, NK cells, myeloid cells
Location of positive cells Regional lymph nodes Peripheral inﬂammatory tissues
Inhibitory roles Inhibition of T cell activation Inhibition of effector T cells and NK cells
Involvement in self-tolerance High Moderate
Phenotypes of gene knockout mice Lethal systemic lymphoperiferative diseases with
polyclonal lymphocyte activation
Non-lethal, individually and strain-dependent differences organ-speciﬁc
autoimmune diseases
Ligand CD80, CD86 PD-L2 (CD273/B7-DC), PD-L1 (CD274/B7-H1)
Ligand expression Antigen-presenting cells (CD80, CD86) Most activated lymphoid cells (PD-L1)
Activated T cells (CD80) Non-lymphoid tissue cells at inﬂammatory sites (PD-L1)
Rare induction on non-lymphoid tissue cells at
inﬂammatory sites (CD80, CD86)
Activated macrophages and dendritic cells (PD-L2)
Ligand expression in tumor cells Inducible but not so often Often inducible
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KC-associated PD-L1 in mucocutaneous inﬂammation [33,41].
K14/PD-L1tg mice overexpress PD-L1 in KCs [33]. In such mice,
CH responses induced by abdominal skin-painting (sensitization)
and subsequent ear skin-painting (challenge) are impaired mark-
edly. Adoptive transfer of hapten-sensitized T cells into K14/PD-
L1tg mice induces lower ear swelling. In PD-L1-overexpressing
skin, the effector function of inﬁltrating CD8+ T cells was impaired
dramatically, but such impairment was abrogated by the addition
of an anti-PD-L1 mAb [33]. Adoptive transfer of PD-1/ OT-I CD8+
T cells into mice expressing OVA in epidermal KCs (K14-OVA mice)
induced severe GVHD-like disease associated with abundant
expression of PD-L1 in all T cells, dendritic cells, Langerhans cells,
and KCs [41]. In addition, knockdown of KC PD-L1 in K14-OVAmice
enhanced activation of OT-I T cells. These results indicate a
requirement for onsite regulation of KC PD-L1 expression via inter-
actions of autoantigen-expressing KCs with autoreactive CD8+ T
cells. In summary, the results indicate that PD-1 is highly
expressed on tissue-recruited effector CD8+ T cells, and that KC-
associated PD-L1 directly suppresses effector T cell generation
and activation at sites of local inﬂammation. Such interaction
between PD-1 and PD-L1 is involved in peripheral tolerance by
preventing excessive local inﬂammatory responses.
PD-L1 expression in SCC and the prognostic implications
thereof
Early reports measured PD-L1 expression in various types of
solid tumor, including squamous cell carcinoma (SCC) of the lung,
esophagus, and head and neck [25,42–44]; other types of carci-
noma of the breast, gut, colon, pancreas, kidney, bladder, and
ovary; and melanomas and glioma [25,45]. PD-L1 was expressed
in 66% (16 of 24) of freshly isolated SCC of the head and neck
(SCCHN) [42]. The extent of histologically determined PD-L1
expression in SCC was not uniform; PD-L1 was found on plasma
membrane and/or in the cytoplasm, but with either focal or diffuse
distribution [25,42,44]. The speciﬁc tumor microenvironment may
greatly affect PD-L1 induction and distinct molecular mechanisms
of such induction may exist. PD-L1 is also expressed at various lev-
els in cultured SCCHN cell lines, and its expression is upregulated
in response to the proinﬂammatory cytokines, IFN-c, TNF-a and
IL-1b [42,44]. As is true of normal tissues, IFN-c is a key cytokine
triggering de novo PD-L1 induction in tumor cells. PD-L1 blockade
by a mAb efﬁciently augmented the effects of adaptive T cell
immunotherapy in a murine model of PD-L1-transfected SCC
(SCCVII) [42] and inhibited the growth of de novo inducedPD-L1+ SCC (NRS-1) [44]. These results suggested the potential
utility of PD-L1 blockade therapy in clinical situations.
In an early clinicopathological study, the expression levels of
both PD-L1 and PD-L2 were analyzed in 52 surgically resected
non-small cell lung carcinoma (NSCLC) patients including those
with SCC and adenocarcinoma [46]. No relationship was evident
for the expression levels of PD-L1 and PD-L2 with either clinico-
pathological variables or postoperative survival; however, in the
same specimens, signiﬁcantly fewer tumor-inﬁltrating lympho-
cytes (TILs) were observed in PD-L1-positive tumor regions, and
the proportions of PD-1+ TILs were signiﬁcantly lower in such
regions. In a study of 41 patients with esophageal SCC, the mRNA
and protein levels encoding PD-L1 and PD-L2 were closely corre-
lated, as assessed immunohistologically [43]. Both PD-L1+ and
PD-L2+ patients experienced signiﬁcantly poorer prognosis than
those who expressed neither form of PD-L, but no signiﬁcant corre-
lation between PD-L1 expression and TIL number was evident [43].
A recent study has found that 39 of 45 cases of oral SCC showed
tumor PD-L1 expression and that the PD-L1 expression level was
related to a lower density of intratumoral CD8+ TILs [47]. However,
the tumor-associated PD-L1 status did not affect survival. In
human papillomavirus (HPV)-associated HNSCC with greater lym-
phocyte inﬁltration, PD-L1 staining in tonsilar SCC was evident on
the membranes of HPV+ tumor cells and CD68+ tumor-associated
macrophages, which correlated with the numbers of CD8+ TILs
expressing high levels of PD-1 [48]. Another study evaluating oro-
pharyngeal SCC showed that PD-L1 was expressed in 49.2% and
34.1% of HPV mRNA-positive and -negative cases, respectively.
No correlation was evident between PD-L1 status and survival
[49]. A more recent study of 340 NSCLC patients, including 178
SCC patients, found that the PD-L1 mRNA and protein expression
levels, as assessed via in situ hybridization and tissue microarray,
respectively, were in agreement, and that high PD-L1 expression
levels were associated with elevated TILs and better survival [50].
SCC studies that explored the correlation between tumor-asso-
ciated PD-L1 status and clinicopathological features and prognosis
have yielded variable results. The methods used to evaluate PD-L1
expression, the timing of biopsy, and the tissue origins differed
among studies, as did the monoclonal/polyclonal antibodies and
detection methods used, the deﬁnition of positive expression,
staining intensities, and staining distributions. It is also possible
that the capacity of PD-L1 to exert opposite effects under different
circumstances contributed to the observed variability. The extent
of lymphocyte inﬁltration and tumor immunogenicity differed
both individually and at the tissue-speciﬁc level. Such factors
may also have affected the results. Further work using larger
Fig. 2. Induction of PD-L1 by various signaling molecules. Signal transduction via PAMPs and IFN-c results in phosphorylation of NF-jB, MAPK (JNK, p38 and ERK), mTOR and
STAT, and downstream signaling mediated by these molecules triggers the nuclear translocation of various transcription factors. Binding of the factors, NF-jB, NFAT, and
STAT/IRF to the PD-L1 promoter further induces transcription and translation of PD-L1.
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deﬁnitive results.Extrinsic control of PD-L1 expression
Up-regulation of PD-L1 in immune cells and several cancer cells
is heavily dependent on TLR- or IFN-c-mediated signaling path-
ways [51–53]. TLR-4 signaling in bladder cancer cells upregulated
PD-L1 expression, and inhibitors of ERK or JNK attenuated such
upregulation [53]. Blockade of the MEK/ERK or MyD88/TRAF6
pathway inhibited the PD-L1 expression induced by IFN-c and
TLR ligands. Signal transduction via IFN-c/STAT1 triggered MEK/
ERK phosphorylation in plasma cells from a multiple myeloma
patient, and inhibition of STAT1 reduced PD-L1 expression [52].
The principal target of IFN-c signaling, interferon regulatory fac-
tor-1 (IRF-1), was also upregulated in plasma cells exposed to
IFN-c, but the levels fell after treatment with ERK inhibitors, sug-
gesting a major role for the MEK/ERK pathway in IFN-c signaling
[52]. In the lung cancer cell line A594, an electrophoretic mobility
shift assay (EMSA), site-directed mutagenesis, and a knockdown
experiment using siRNA all revealed that IRF-1 was primarily
responsible for both constitutive PD-L1 expression and early
induction of PD-L1 after IFN-c stimulation. In addition, IRF1
synthesized de novo, acting through the JAK/STAT pathway was
involved in late induction of PD-L1 [35]. In myelodysplastic
syndrome blast cells, PD-L1 was upregulated via NF-kB activation
in response to IFN-c and TNF-a [54]. IFN-c-stimulated dermal
ﬁbroblasts exhibited nuclear translocation of NF-jB mediated by
phosphorylation of ERK1/2 and PI3K, increasing PD-L1 promoter
activity and gene expression [55]. Knockdown of PKD2, a down-
stream target of PI3K activated by PKC, decreased PD-L1 expression
in IFN-c-stimulated human oral SCC [56]. In addition, severalmicroRNAs (miR), single-stranded RNA molecules that repress
translation and silence genes, have been shown to regulate PD-L1
induction, post-transcriptionally. miR-513 directly regulated PD-
L1 mRNA and protein expression by targeting the PD-L1 3-untrans-
lated region in human biliary epithelial cells stimulated by IFN-c
[57].
All above results suggest that extrinsic stimuli acting via TLRs or
IFN-c receptor modulate the expression and activation of various
down-stream signaling molecules, such as NF-kB, MAPK, PI3K,
mTOR and JAK/STAT, that affect cell cycle progression, cell prolifer-
ation, and activation or regulation of transcription factors. Such
signaling molecules further regulate the nuclear translocation of
transcription factors to the PD-L1 promoter (Fig. 2 and Table 2).Intrinsic cellular control of PD-L1 expression and
carcinogenesis
Apart from the data summarized above, several reports have
suggested that intrinsic cellular changes associated with
carcinogenesis induce PD-L1 expression (Table 2 and Fig. 3). PD-
L1 expression in human breast cancer is strongly associated with
proliferative Ki-67 expression and cell cycle progression that is
independent of host PD-1 [58]. T cell lymphoma cells carrying
the oncogenic nucleophosmin (NPM)-anaplastic lymphoma kinase
(ALK), which is involved in malignant transformation, induce high
levels of PD-L1 expression via STAT3 and ERK activation [59,60].
Inactivation of the tumor suppressor gene phosphatase and tensin
homolog (PTEN) is often observed in mouse SCC [61,62]. PTEN neg-
atively regulates the phosphatidylinositol 3-kinase (PI3K)/AKT
pathway, alternations of which are also evident in human SCC,
together with a reduction in/loss of PTEN. In human glioma, loss
of PTEN has been correlated with enhanced PD-L1 expression
Table 2
Signaling molecules involved in PD-L1 induction.
Cell type Triggering factor Signaling molecule involved Reference
Normal cell
Mouse
Keratinocyte (overexpressing PD-L1) Carcinogenesis Slug, Twist 23, 57
Human
Biliary epithelial cell IFN-c miR-513 48
Dermal ﬁbroblast IFN-c PI3K, ERK1/2, NF-jB 46
Cancer cell
Mouse
SCCHN Carcinogenesis (Loss of PTEN) PI3K/Akt/mTOR 61
Lung SCC Inactivation of Lkb1 and PTEN Kras, PI3K 65
Human
Bladder cancer cell TLR-4L MEK/ERK 53
Breast cancer cell Carcinogenesis Ki-67 58
Colorectal cancer miR-20b, -21, -130 PI3K 63
Glioma Loss of PTEN PI3K/Akt 45
Lung adenocarcinoma epithelial cell IFN-c JAK/STAT/IRF-1 35
MM plasma cell IFN-c STAT1, MEK/ERK 52
TLR-2L, TLR-4L, TLR-9L MyD88/TRAF6
Myelodysplastic syndrome blast cell IFN-c, TNF-a NF-jB 54
Oral SCC IFN-c PI3K, PKC, PKD2 56
T cell lymphoma NPM-ALK STAT3, ERK1/2 59, 60
PTEN (phosphatase and tensin homolog); Lkb1 (liver kinase B1); TLR (Toll-like receptor); IFN (interferon); TNF (tumor necrosis factor) NPM-ALK (neucleophosmin-anaplastic
lymphoma kinase); PI3K (phosphoinositide 3-kinase); ERK (extracellular signal-regulated kinase); NF-jB (nuclear factor kappa-light-chain-enhancer of activated B cells); Akt
(or PKB or protein kinase B); mTOR (mammalian target of rapamycin); Kras (Kirsten rat sarcoma viral oncogene homolog); MEK (mitogen-activated protein kinase kinase);
JAK (Janus kinase); STAT (signal transducer and activator for transcription); IRF (interferon regulatory factor); MyD88 (myeloid differentiation primary response gene 88);
TRAF (tumor necrosis factor receptor associated factor); PKC (protein kinase C); PKD (protein kinase D).
Fig. 3. Related signaling molecules for PD-L1 induction and carcinogenesis. PAMPs, growth factors, and cytokine stimulation transduces signals via MyD88/IKK/NF-jB, JAK/
STAT/IRF1, PI3K/Akt/mTOR/S6K and MAPK/Jun/Fos, triggering PD-L1 upregulation. In addition, PTEN and Lkb1 negatively regulate PI3K/Akt and/or mTOR-mediated signaling,
resulting in modulation of PD-L1 expression. These signaling molecules also link to cell intrinsic alternation related to carcinogenesis, such as cell cycle, cell proliferation,
adhesion, migration, and EMT. PI3K/Akt and MAPK are the upstream events of Wnt/b-catenin. Snail/E-cadherin and MyD88/IKK/NF-jB pathways directly control cell cycle,
proliferation, adhesion and migration.
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Fig. 4. A possible link between PD-L1 induction and malignant conversion. Inﬂammatory mediators such as cytokines and growth factors cause transient induction of PD-L1
expression in epithelial cells. However, continuous and/or repeated stimuli (chronic inﬂammation) may induce irreversible cell intrinsic changes that promote EMT and
carcinogenesis in addition to PD-L1 induction. Tumor-associated PD-L1 regulates the host immune responses and promotes tumor progression.
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expression, resulting in PD-L1 overexpression [63]. The KC-speciﬁc
deﬁciency of PTEN induced epidermal hyperplasia and accelerated
tumor formation [64]. Simultaneous activation of Kras and inacti-
vation of Lkb1 (also known as serine-threonine kinase 11) induce
lung SCC formation. Although a deﬁciency of either PTEN or Lkb1
did not drive tumor formation, simultaneous inactivation of PTEN
and Lkb1 resulted in the development of murine lung SCC exhibit-
ing elevated PD-L1 expression [65]. One of the most frequently
mutated oncogenes in patients with NSCLC is the epidermal
growth factor receptor (EGFR) gene. Recent reports demonstrated
that activating EGFR mutations were associated with increased
PD-L1 expression in surgically resected NSCLC and ectopic expres-
sion of mutant EGFR in bronchial epithelial cells induced PD-L1
expression [66,67]. Inhibition of EGFR signaling by the EGFR tyro-
sine kinase inhibitor erlotinib downregulated surface expression of
PD-L1 in EGFR mutation-positive NSCLCL cells, but not in the EGFR
wild-type cells [67]. These results suggest a possible link between
carcinogenesis and PD-L1 expression.
The epithelial–mesenchymal transition (EMT) is critical in the
conversion of normal epithelial cell to tumor cell during SCC
carcinogenesis. Down-regulation of E-cadherin and up-regulation
of N-cadherin are closely with such a conversion. We reported that
PD-L1 transgenic mice overexpressing PD-L1 in KCs (K14/PD-L1tg
mice) [33] exhibited clearly accelerated SCC formation in a carcin-
ogen 3-methylcholanthrene (MCA)-induced tumor model [33,68].
Prior to tumor formation, atypical cellular changes such as dis-
turbed cell alignment and chromatin condensation were evident
in basal cells of K14/PD-L1tg mice at an early stage of MCA injec-
tion. E-cadherin expression was down-regulated signiﬁcantly in
PD-L1-overexpressing KCs. Regulation of E-cadherin expression is
controlled by the Snail family of transcriptional repressors
[69,70]. We found that K14/PD-L1tg-derived SCC exhibited signiﬁ-
cantly higher levels of Slug (Snai2) and Twist (Twist1) than those of
wild type mice-derived SCC. Slug and Twist may play critical roles
in epithelial KC migration by repressing E-cadherin.
In KCs, ultraviolet radiation activates the ERK and p38MAPK cas-
cades and increases Snail and Slug expression [71]. Wnt/b-cateninpathways are also involved in the EMT process [72]. Overexpression
of Akt in SCC lines caused EMT characterized by down-regulation of
numerous epithelial cell-speciﬁc proteins, including E-cadherin and
b-catenin [73]. Various downstream signaling cascades triggered by
growth factor receptors, such as Akt/mTOR, NF-kB and MAPK, are
involved in the EMT. Most EMT-related signalingmolecules overlap
with those involved in extrinsic induction of PD-L1, as described
above (Fig. 3). Therefore, it is difﬁcult to differentiate the precise
events induced by exogenous stimuli from changes intrinsic to cells.
It is conceivable that the persistent PD-L1-induced exogenous stim-
uli may transduce constitutive signals that activate expression of
intracellular proteins required for the EMT and carcinogenesis
(Fig. 4). It seems that elevated tumor-associated PD-L1 levels are
caused not only by exposure to extracellular cytokines secreted by
tumor bystander cells, but also by intrinsic cancerous changes
linked to the EMT and carcinogenesis.Concluding remarks
Over the past decade, appreciation of the utility of anti-PD-1 or
anti-PD-L1 therapy has grown. Taube et al. commented that one of
the most intriguing ﬁndings from early clinical trials evaluating
PD-1 pathway blockade therapy to treat advanced solid tumors
was the correlation between pretreatment tumor PD-L1 expression
and treatment response [21]. Most tumors in the patients from ear-
lier clinical trials were melanoma, NSCLC, and renal-cell cancers,
that which are all rather highly immunogenic and exhibit higher
levels of lymphocyte inﬁltration. A more recent large-scale study
involving 636 primary breast carcinoma patients demonstrated
that half of all breast cancer expressed PD-L1 mRNA [74,75].
Higher PD-L1 mRNA expression levels are associated closely with
elevated TIL numbers and longer recurrence-free survival.
However, only 16% of breast cancers showed prominent TIL inﬁl-
tration, whereas 12% showed both high TIL numbers and PD-L1
expression. This implies that the majority of breast cancers (46%)
exhibited PD-L1 expression but low TIL numbers. Such a patient
group would beneﬁt less from PD-1 blockade therapy alone, since
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responsible for PD-L1 expression. In such a group, additional treat-
ments to modulate intracellular signaling associated with cell
malignancy and/or to stimulate immune cell recruitment to
tumors may be required. Although no large-scale study has been
performed in SCCHN patients to evaluate the correlation between
PD-L1 expression and TILs, such patients are often immunocom-
promised because of active immune regulation by tumor-
associated macrophages, myeloid-derived suppressor cells, and
regulatory T cells [76]. In addition, cytogenetic alternations are
often seen in SCCHN [77]. A phase III clinical trial of nivolumab
versus cetuximab, methotrexate or docetaxel (as chosen by physi-
cians) in patients with recurrent or metastatic SCCHN
(NCT02105636) presently is ongoing. Consideration of PD-L1
expression mechanisms will be important to optimize treatment
approaches in SCCHN patients.Conﬂict of Interest
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